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Cooperation
Clinical chemists ’discovered’ automation some twenty years
ago and, as instrument users, have spent these last two decades
alternating between hope and deception. They are now
disillusioned people. Each year brings a fresh crop of original
systems, but chemists have found that they have only one
chance in ten of purchasing a useful instrument since there is
no way of telling the good from the bad on an exhibition
stand.
remember a closed meeting held in Munich in 1978
between users and suppliers of laboratory products, which
discussed the recurring problems of communication and
cooperation. A top executive of a leading company, apparently
exasperated by the usual mistrusting comments of the
laboratory professionals, suddenly burst out ’The instrument
companies have raised your profession to its present status.
Without us you would still be playing with test tubes and
bunsen burners down in the basements of your hospitals!
You can’t just go on ignoring what you owe to industry,
treating us as junior partners, closing the door in our faces
when we try to join your panels but at the same time asking
for more and more free reagent samples and unlimited,
unconditional instrument evaluation This is the gist
of what he said, but he was most sincerely upset by the
reaction of the laboratory professionals.
Meanwhile, was wondering why it was that an instrument
evaluation in perhaps another country or by a different
laboratory is never good enough for one’s own purposes.
Instrument evaluation is a highly expensive activity in our
laboratories even without such duplication. realized then
that wasn’t the only one to be unhappy with the situation,
and that the communication gap was probably much larger
than had suspected. No matter how much closer to each
other the two sides may draw, cannot see the clinical chemist
feeling indebted to industry for having contributed to the
present status of his profession, nor will he expect any
acknowledgement from industry. Cooperation in this context
simply means that we try to add rather than cancel our
respective efforts and expertise in an area ofcommon interest.
It is a means to self-realization, and has not a great deal to do
with mutual support.
Indeed, we can only agree on means: our aims are different.
Industry sells, we analyse. The common area is the instrument,
but its definition is equivocal: for industry it is a product, to
us it is a tool. And all too often it is prototype and a nuisance.
Good communication must be sought at a still more basic
level. Only when we have agreed proper definitions for such
terms as ’sample throughput’, ’throughput time’, ’volume
ratio’, ’photometric accuracy’, ’carry-over’ etc., will those
terms carry unequivocal information.
The role of industry as a leading force in the technological
development of laboratories cannot be questioned. What can
be questioned is the ultimate value of this development for
which industry cannot be completely blameless. The truth
is that we have no reason to be too proud of clinical chemica!
practice today. But if industry insists on sharing credit for
our successes, it must also be prepared to accept some respons-
ibility for our failures.
It is not my intention here to detail the successes, since
they have been exhaustively discussed elsewhere ]. It is
undeniable that the remarkable improvements in kinetic
analysis or particle counting, for example, owe a great deal
to new technologies and demonstrate that cooperation can
be fruitful. For the purpose of this paper I would like to
elaborate on the three points introduced above: the unhappin-
ess, the communication gap, and the degradation of clinical
laboratory practice. will then conclude with the user’s
needs.
As a preface, let me make one general statement: am
neither complaining, nor casting stones. am trying to
understand. People are no better and no worse whether they
belong to industry, to scholarship, or to medicine. However,
the systems, i.e. the existing relationship between each
decision group, must be criticized. This is a prerequisite for
positive change, which in turn can only come from individual
initiatives.
Unhappiness
have been but a moderately satisfied user of automated
instruments for more than ten years (automated or mech-
anized let us not play with definitions for once: everything
beyond the Dubosq colorimeter can be called automated).
My experience is that high-capacity instruments do not
completely solve our problems. The manpower costs we save
on performing analyses will be required for evaluating,
calibrating, and maintaining the instruments. Even when the
instruments are of clever design, they are often unreliable in
performance and construction; the run-in time is too long,
often over six months; the training of operators non-existent;
the breakdowns too frequent; the service poor. Powerful
instruments can demand that the laboratory is re-organized
around them with little obvious advantage. As such they
disorganise the existing structure and make themselves even
more unrewarding for the staff. They build up bottle-necks
because speed is often sacrified for automation. Details of
such dissatisfaction are available elsewhere. Every statement
in the recently issued IUPAC document on the subject [2],
addresses a problem encountered in present day instruments.
Some statements are almost funny, like that on interaction
within the instrument. This could better read ’an instrument
should not destroy itself’.
Communication?
thus have unsatisfied needs which believe can describe in
detail and for which technologically and economically sound
solutions must exist. However, am not sure that can
convince anybody. In fact, don’t think manufacturers are
really interested.
Let us consider the Du Pont ’aca’, for example. To me it is
a Mack box which surrenders the clinical chemist, handcuffed,
to one company. My definition of a black box here is an
instrument with an input and an output and something in
between which you are not really interested in because you
cannot do anything about it when it fails. Even calibration
and quality control are biased concepts with this machine.
am an analyst, and look at a clinical laboratory as a living
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entity with tests, methods, and instruments that are born,
live, and die, with an average life, and a thrilling one, of
perhaps five to seven years. An ’aca’ would make my laborat-
ory sick. But what is the point of claiming thatthe instrument
is ill-conceived when it was obviously well enough conceived
to allow the manufacturers to sell over a thousand (approx-
imately 1800 sold up to July 1979) units around the world,
some to quite prestigious laboratories? The instrument entered
the world market as a routine instrument and not just as a
prototype, and it was among the very few that stood up to
the harsh demands of the laboratory. It was thus selected
by our institutions as one of the more useful instruments, if
not the best in scientific terms. The struggle for survival
involves characteristics other than those of pure analysis,
such as ease of use, ruggedness, training and servicing, updating
of application, etc. The ’aca’ is a success. It is simply a matter
of viewpoint. If there is a market for such ’package-processors’
or if, more generally, a sufficient proportion of users do not
object to being forced to buy their reagents and methods
from the instrument manufacturer, then merger and consoli-
dated policy will continue until the trend towards such systems
becomes irreversible whatever the consequence to our freedom
of choice and ultimately to health care.
Industry, by its very nature, looks for markets; the larger
the return and the shorter the term the better. It may be that
the need think have identified represents such a market.
But it is more likely that a slightly different need will represent
a better market. So the manufacturer will shift his target and
try to persuade me that he knows my need better than do.
Sometimes this is done quite sincerely. For example, laborat-
ory people originally wanted a facility for specimen-splitting
in order to distribute labelled material to the bench,
together with the work sheet, and so retain the measuring
instrument of their choice at each working station. They are
still waiting. Some limited attempts were made in the late
1960’s. One by Beckman was stillborn. Another by Siemens
was dropped only recently after some ten years of painful
prototyping. Today’s solution, if the project were to be
restarted from zero, might be extremely elegant and so-called
’limited automation’ would do the rest. However, by now
most of us have given up the idea and have learnt to accept
those monstrous multichannel instruments nobody ever
asked for. And we have even started to believe that we
needed this sort of equipment to solve our internal organi-
zation problems. One tube twelve or twenty results: a
dream! Or a nightmare when it comes to the inevitable
analytical compromises, the failure rate and restart problems,
the lack of flexibility, the staff-rejection syndrome etc. The
actual efficiency of high-capacity analyzers is grossly over-
estimated. Very often they require more time for start-up
and shut-down than for analyses. As a rule, one measurement
out of three or four is for calibration, control, or re-checking.
These systems are praised for their administrative qualities
but they are directly responsible for our administrative
problems. It is a vicious circle.
The manufacturer seldom seems aware of the mismatch.
He has learnt to deal with his customer as somebody who
expects results on blood tests. He comes with simple ideas
such as that any test can be performed if you can 1) dilute a
sample; 2) add one or two reagents; 3) wait for some time;
4) read an absorbance. Or: a test result is either normal or
abnormal; normal means healthy, abnormal means sick! He
has only a superficial idea of his interlocutor’s real concerns.
In particular, he seems to ignore the permanent stress (or
distress) that can result from an unreliable instrument. His
own motivation is simple: he wants to sell. The clinical
chemist’s motivation is complex. His ambitions usually go
beyond the mere output of results. He is concerned with how
they are obtained and what to use them for. His academic
training leaves him ill-prepared to run the industry-like prod-
uction systems which our laboratories tend to become and
which manufacturers or their representatives think they
understand. And this obscures his critical sense. It is also true
that some of his demands are extravagant and that he has little
idea of their implicit costs. The management of our laborat-
ories is not an easy task, and the manufacturer can only come
up with very partial solutions to the problems.
Communication problems of a similar nature can some-
times be found inside the instrument company itself, between
the more user-oriented R & D or applications people on the
one hand, and an over-zealous marketing department on the
other. A number of gross failures can be traced back to the
latter releasing immature and therefore unviable instruments
against the advice of the former.
But let me now depart from this basic criticism and
assume automated instruments that perform reliably and sell.
Should not these prove that demand has been fulfilled? Not
really, because they never coincide with the average user’s
need. And this is because there is no average user. There are
only users, and here manufacturers deserve credit for finding
their way through such a diversity of behaviours and ment-
alities.
Laboratory practice
Modern health care systems have become large consumers
(one might even suggest wasters) of laboratory data. The
trend, though slowing down, has not yet reversed. In France,
for example, the cost of analyses shows an increase of 22% in
1978 i.e. larger than that (18.5%) oftotal medical consumption
(price and volume contributed to these figures in a ratio of
to 1). Mass producing clinical chemistry is young and un-
settled. Whether justified or biased, markets for instruments
and reagents have expanded at a very unusual rate during the
past 25. years, producing new demands, not always unselfish,
among the professional and economic sectors concerned and
provoking some dramatic financial failures. People producing
laboratory data call themselves clinical biochemists, medical
biologists, laboratory doctors, chemical pathologists, or even
biological pharmacists, what they are called depends upon
their geographical location as much as anything else. To be
complete, one Should include the very large group of medical
technicians often working quite independently under the
formal responsibility of a physician and last but not insignifi-
cant, the group of devoted doctors’ wives who often fulfil
this function. All these people operate in a widely variable
and sometimes unstable cultural, economic, technical, and
legal environment. Their training, if any, usually includes
both medical and chemical curricula, but again in a highly
variable proportion.
Within almost every country a more or less active compet-
ition exists between doctors and chemists for the control of
laboratories. This is more of a stimulus in those countries
where regulations have clearly delineated the fights and duties
of each partner group; in France, for instance, where prescrip-
tion and invoicing of tests cannot be carried out by the
same agency. It is a source of considerable qualitative and
quantitative bias in the instrument and reagent markets of
countries where self-requesting prevails among the producers
of laboratory results. In Switzerland about 50% of total
medical consumption occurs outside the hospital system
(500 hospitals), 5% of which, i.e. 10% of direct medical costs,
are for analyses but only 1% goes through an approved
laboratory. The remaining 9% (around 500 million SF)
is directly charged by doctors performing tests in their own
laboratory. In Germany over, 65% of total medical consump-
tion is extra-hospital (this and all subsequent figures are for
1976). Laboratory costs represent about 5% of this. They are
charged by 400 private laboratories (working partly for
hospitals too) and 25,000 private practitioners. The latter
perform 20% of all clinical chemical tests in the country,
creating an unusually large market for small kits and so-
called monotests, with the corresponding increase in price
and quality control problems or, more likely just quality
problems. They also perform 60% of all urine-screening,
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doubling the number of such strip tests per patient compared
to France. Since these kits are twice as expensive, the German-
to-French ratio for this specific market is five to one, account-
ing for the difference in the size of population.
In such a situation control of the choice of tests, amount
ordered, quality of result, and profit is entirely shared
between the doctor and the manufacturer. The latter, being
the more competent and better organized of both partners, is
in a very strong position to advise his customer, particularly
about methods and instruments. Until paying third-parties
and/or patients become aware of the situation, willing to
question the clinical justification of the request and
sufficiently organized to do so, the trend cannot be expected
to reverse. And the clinical chemist can have no influence in
this case as he is completely outside the flowchart. There are
cases, however where perhaps he could exert influence such
as in the French hospitals where 32% vf all chemical tests are
five electolytes (Na, K, CI, Ca, P). An extraordinary figure,
which it is tempting to link with the undoubted success of
Technicon’s SMA in that country.
Whether they are created by economic or legal factors and
maintained by profit groups, or clinically and scientifically
justified, there are considerable quantitative and qualitative
differences between the two major European countries in
their approach to analyses. The Germans spend exactly twice
as much as the French per inhabitant for analyses, doing 6
tests where the French do 3.8. The additional 2.2 are mainly
glucose and enzymes (the Germans do twice as many glucose
tests per inhabitant as the French). The costs of instruments
and reagents, however, are about the same in both countries.
France is proportionately more automated than Germany.
The Germans seem to ignore the use of calcium and potassium
measurements. They do much more coagulation testing
because they use prothrombin time as a hepatic parameter.
Because of legal hindrance the French do four times fewer
RIA’s etc. Most of these figures come from a recent work
by Schoff 3 ], which casts a searching light on our profession.
Obtaining similar data for other European countries would
not only show the priorities for standardization, but would
also teach us humility" there are also communication gaps
within the profession. But there are common features also:
screening, profiling, defensive medicine, and short term profit
combine to generate a systematic over-production and under-
utilization of data. And industry shares the responsibility for
this.
Let me complete this rather chaotic picture by insisting
that the average quality of our results is still far from satis-
factory and homogeneous, however tired we may be of harking
back to the same old story. Automated instruments enable
us to measure more specimens for more parameters but they
are given undeserved credit for improving the quality of test
results. Quality surveys constantly show that long term
precision and accuracy of manual methods are just as good or
even better. It is the quality of instruments and the value of
calibrators, not the degree of mechanization, that have a
decisive influence on the quality of results.
User’s needs
Looking for the user in order to identify his needs, have
been obliged to recognize a dramatic lack of coherence and
efficiency in our profession. There is a danger that, having
failed so far to present an organized front, clinical chemistry
will be degraded into a number of marketing outlets and
eventually retrieved by industry with the tacit approval of
government, just like another pharmaceutical business. As
everyone knows, drug inflation is considerably worse and less
justified than test inflation and there is hardly any intermed-
iary between the doctor and the manufacturer. Pharmaceutical
companies are in a position where they can consciously dis-
inform the physician, for example dissuading him from
controlling his patients’s drug levels, such as digoxin. Control
of drug level would soon demonstrate the gross overdosage
of these chemicals in the population and consequently
compromise sales.
It is now a race against time. The twin origins of clinical
chemistry make both for its wealth and its weakness. Each of
us inevitably leans more either to the chemical or to the
clinical side, so that each of us has his Achilles’ heel. Industry,
logically, has taken advantage of this duality from the very
beginning, forcing oversimplified analytical concepts into the
clinically-minded, and rudiments of diagnostics into the
analytically minded. This is how such odd instruments as the
Auto Analyzer were so widely accepted and how such non-
tests as the CEA (carcino-embryonic antigen) test manage
to enter the market. We must not allow industry to simplify
our investigational methods into a caricature and immobilize
our profession to a sterile infantilism.
Our laboratories and, more specifically, our instruments,
are components of a formidable venture called health care.
Health care, Ralph Nader has said is a cost-plus, increasingly
no-fault industry with no incentive to reduce costs. And he
might have added ’or to increase efficiency’. Unlike other
businesses, our laboratories are production systems with no
feedback be it from the doctor, the patient, or anyone else.
This endows us with a considerable responsibility if we
believe that clinical chemistry can contribute to improving
people’s living. We are alone and free to decide what we are
going to demand, to accept, and to refuse. am convinced
that we could have avoided the dinosaurs.
am not sure that industry should have concerned itself
with the diagnostic use of tests or even with analytical methods.
Making appropriate analytical instruments could have been
sufficient. But now that it has entered the clinical field,
advising on the relative merits of tests, industry should involve
itself much further with the problem; it should invest in
training, learn about biological variation and statistics,clinical
relevance, parametric testing etc., instead of simply laying
out another advertisement each time a new test is discovered
and trying to sell it like a new vitamin preparation. And this
will require much closer and more systematic cooperation
with the profession (the emerging European Committee for
Clinical Laboratory Standards, ECCLS, may be the framework
for such cooperation). As far as instruments are concerned
we would like them to be rugged and safe. Material and
reagent should be used at the ultramicro level. Measuring
devices should be accurate and stable. Flexibility should result
from modularity and miniaturization. Mechanical movements
should be quick: much quicker than their manual counter-
parts. Instruments should stem from a systems analysis of
every aspect of laboratory work from and including blood
withdrawal to reporting. Every available analytical technique
should be envisaged, not just visible absorption spectometry.
And additionally all these facets may be automated why
not?
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